Framework for personalized prediction of treatment response in relapsing remitting multiple sclerosis

Table 10 Comparison of therapy effectiveness for the CDP model

DMT*	Slope coefficient^a	Sample size when DMT* was taken	Sample size when DMT* was not taken	p-Value
Dimethylfumarat	−0.5363	863	306	0.027
Fingolimod	0.1114	135	87	0.792
Glatirameracetat	−0.5336	238	45	0.350
Natalizumab	−0.4021	1101	132	0.405
Teriflunomide	−0.4317	179	16	0.730

DMT* highest ranked disease modifying therapy.
^a Derived from a survey-weighted quasi-binomial generalized linear model where negative sign indicates lower disease activity

ISSN: 1471-2288